$0.59
+1.83%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.58
From 52W high−76.39%
Volume6.98M
Market cap$162.68M
P/E (TTM)—
P/S (TTM)76.7x
Div yield—
Key dataSep 18, 2026
Open
$0.58
From 52W high
−76.39%
Volume
6.98M
Market cap
$162.68M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
44.8
MomentumView details →
1D Return
+1.83%
YTD Return
−39.23%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte, Inc. (HUMA) shares closed at $0.59, up 2.23% from the previous close.1d agoThe U.S. Food and Drug Administration authorized Humacyte to extend the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated at 2°C to 8°C.11d agoHumacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.39d ago